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Definitions
Joint models for longitudinal and time-to-event data
• Methods to simultaneously model potentially related longitudinal and time-to-event data
• Often used to account for study dropout in longitudinal studies, to include a time varying covariate 
measured with error in time-to-event studies, or to investigate association between longitudinal 
and time-to-event outcomes
• Longitudinal sub-model and time-to-event sub-model linked through an association structure
• Many association structures exist – each with different interpretations.  Here only random effects 
only proportional association considered
Meta-analysis
• Systematic pooling of results from multiple studies
• Allows increased precision, identification of effect sizes too small to be identified in single studies, 
and allows questions additional to those originally posed in the data to be answered
• Gold standard – Individual Participant/Patient Data (IPD) meta-analyses, where data for each 
individual recorded in studies identified in the meta-analysis is available.
The multi – study case, meta-analysis
Study 𝑘 for 𝑘 in 1…𝐾
Individual 𝑖 for 𝑖 in 1…𝑛𝑘
Longitudinal measurements at 
time points j for 𝑗 in 1…𝑚𝑘𝑖
Study
Ind Ind Ind
Time 1 Time 2 Time 3 Time 2Time 1Time 1
Considerations with multi study joint data
• Data from different studies likely to display heterogeneity, which needs to be accounted for
• Fixed interaction terms
• Stratified baseline hazard in survival sub-model
• Study level random effects
• Large datasets – issues fitting on individual computers
• Estimation of standard errors
• Approximate standard error procedures – inaccurate if model includes study level random effects
• Bootstrapping – time consuming
• Estimation of random effects
• Difficulties with adaptive Gaussian quadrature – multi-level random effects potentially different 
specifications at each level
• Pseudo – adaptive procedure used – calculate position and spread of random effects at each level 
based on the initial longitudinal fit.  
Real Dataset – subset of INDANA dataset
• IPD from multiple studies investigating the effect of no treatment versus any treatment 
for hypertensive patients
• Longitudinal data measured at 6 months, then annually thereafter to maximum of 7 years.  
Measurement patterns varied between studies
• Using subset with data for longitudinal outcome systolic blood pressure (SBP) and time to 
death, data available from 6 studies.  Data subset used as  available computer didn’t have 
sufficient memory for the full dataset.  Proportions of individuals from each study, and 
proportions events/censored within each study kept same as full dataset
• Evidence of a changepoint in the data at 6 month, so time and treatment allowed 
different coefficients before and after changepoint
joineRmeta
• Package developed as extension to joineR package
• Currently one stage model permits
• Random effects only proportional sharing structure
• One continuous longitudinal outcome and one possibly censored time-to-event 
outcome
• One changepoint permitted, with ability to specify variables to take different 
coefficients before and after.  Changepoint is optional
• Individual and study level random effects permitted, capped at 3 per level
• Baseline hazard can be common across studies or stratified by study
• Package also contains (but not demonstrated here) :
• Functions to easily plot multi-study joint data
• Multi-study joint data simulation function
• Function for second stage of two stage MA to pool joint model fits
Model group definitions – Group 0 – Naïve model
Longitudinal sub-model
𝑌𝑘𝑖 = 𝛽10 + 𝛽11𝑡𝑖𝑚𝑒 + 𝛽12𝑡𝑟𝑒𝑎𝑡
+ 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒 + 𝜀𝑘𝑖
Time-to-event sub-model
𝜆𝑘𝑖 𝑡 = 𝜆0 𝑡 exp 𝛽21𝑡𝑟𝑒𝑎𝑡 + 𝑊2
Association Structure
𝑊2 ∝ 𝑊1
𝑊2 = 𝛼
(2) 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒
Key – model components accounting for 
between study heterogeneity
 Longitudinal fixed effect coefficients
 Time-to-event fixed effect coefficients
 Study level random effects
 Baseline hazard stratified by study
Model group definitions – Group 1 – Fixed effects
Longitudinal sub-model
𝑌𝑘𝑖 = 𝛽10 + 𝛽11𝑡𝑖𝑚𝑒 + 𝛽12𝑡𝑟𝑒𝑎𝑡
+ 𝛽13𝑠𝑡𝑢𝑑𝑦
+𝛽14𝑡𝑟𝑒𝑎𝑡 ∗ 𝑠𝑡𝑢𝑑𝑦
+ 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒 + 𝜀𝑘𝑖
Time-to-event sub-model
𝜆𝑘𝑖 𝑡
= 𝜆0 𝑡 exp 𝛽21𝑡𝑟𝑒𝑎𝑡 + 𝛽22𝑠𝑡𝑢𝑑𝑦 + 𝛽23𝑡𝑟𝑒𝑎𝑡 ∗ 𝑠𝑡𝑢𝑑𝑦 + 𝑊2
Association Structure
𝑊2 ∝ 𝑊1
𝑊2 = 𝛼
(2) 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒
Key – model components accounting for 
between study heterogeneity
 Longitudinal fixed effect coefficients
 Time-to-event fixed effect coefficients
 Study level random effects
 Baseline hazard stratified by study
Model group definitions – Group 1 – Fixed effects
Longitudinal sub-model
𝑌𝑘𝑖 = 𝛽10 + 𝛽11𝑡𝑖𝑚𝑒 + 𝛽12𝑡𝑟𝑒𝑎𝑡
+ 𝛽13𝑠𝑡𝑢𝑑𝑦
+𝛽14𝑡𝑟𝑒𝑎𝑡 ∗ 𝑠𝑡𝑢𝑑𝑦
+ 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒 + 𝜀𝑘𝑖
Time-to-event sub-model
𝜆𝑘𝑖 𝑡
= 𝜆0 𝑡 exp 𝛽21𝑡𝑟𝑒𝑎𝑡 + 𝛽22𝑠𝑡𝑢𝑑𝑦 + 𝛽23𝑡𝑟𝑒𝑎𝑡 ∗ 𝑠𝑡𝑢𝑑𝑦 + 𝑊2
Association Structure
𝑊2 ∝ 𝑊1
𝑊2 = 𝛼
(2) 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒
Key – model components accounting for 
between study heterogeneity
 Longitudinal fixed effect coefficients
 Time-to-event fixed effect coefficients
 Study level random effects
 Baseline hazard stratified by study
Model group definitions – Group 2 – Fixed effects and one study level 
random effect
Longitudinal sub-model
𝑌𝑘𝑖 = 𝛽10 + 𝛽11𝑡𝑖𝑚𝑒 + 𝛽12𝑡𝑟𝑒𝑎𝑡
+ 𝛽13𝑠𝑡𝑢𝑑𝑦
+ 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒
+𝑏1𝑘
(3)
𝑡𝑟𝑒𝑎𝑡 + 𝜀𝑘𝑖
Time-to-event sub-model
𝜆𝑘𝑖 𝑡
= 𝜆0 𝑡 exp 𝛽21𝑡𝑟𝑒𝑎𝑡 + 𝛽22𝑠𝑡𝑢𝑑𝑦 + 𝑊2
Association Structure
𝑊2 ∝ 𝑊1
𝑊2 = 𝛼
(2) 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒 + 𝛼(3) 𝑏1𝑘
(3)
𝑡𝑟𝑒𝑎𝑡
Key – model components accounting for 
between study heterogeneity
 Longitudinal fixed effect coefficients
 Time-to-event fixed effect coefficients
 Study level random effects
 Baseline hazard stratified by study
Model group definitions – Group 2 – Fixed effects and one study level 
random effect
Longitudinal sub-model
𝑌𝑘𝑖 = 𝛽10 + 𝛽11𝑡𝑖𝑚𝑒 + 𝛽12𝑡𝑟𝑒𝑎𝑡
+ 𝛽13𝑠𝑡𝑢𝑑𝑦
+ 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒
+𝑏1𝑘
(3)
𝑡𝑟𝑒𝑎𝑡 + 𝜀𝑘𝑖
Time-to-event sub-model
𝜆𝑘𝑖 𝑡
= 𝜆0 𝑡 exp 𝛽21𝑡𝑟𝑒𝑎𝑡 + 𝛽22𝑠𝑡𝑢𝑑𝑦 + 𝑊2
Association Structure
𝑊2 ∝ 𝑊1
𝑊2 = 𝛼
(2) 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒 + 𝛼(3) 𝑏1𝑘
(3)
𝑡𝑟𝑒𝑎𝑡
Key – model components accounting for 
between study heterogeneity
 Longitudinal fixed effect coefficients
 Time-to-event fixed effect coefficients
 Study level random effects
 Baseline hazard stratified by study
Model group definitions – Group 3 – Fixed effects and two study level random 
effects
Longitudinal sub-model
𝑌𝑘𝑖 = 𝛽10 + 𝛽11𝑡𝑖𝑚𝑒 + 𝛽12𝑡𝑟𝑒𝑎𝑡
+ 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒
+ 𝑏0𝑘
(3)
+ 𝑏1𝑘
(3)
𝑡𝑟𝑒𝑎𝑡 + 𝜀𝑘𝑖
Time-to-event sub-model
𝜆𝑘𝑖 𝑡 = 𝜆0 𝑡 exp 𝛽21𝑡𝑟𝑒𝑎𝑡 + 𝑊2
Association Structure
𝑊2 ∝ 𝑊1
𝑊2 = 𝛼
(2) 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒 + 𝛼(3) 𝑏0𝑘
(3)
+ 𝑏1𝑘
(3)
𝑡𝑟𝑒𝑎𝑡
Key – model components accounting for 
between study heterogeneity
 Longitudinal fixed effect coefficients
 Time-to-event fixed effect coefficients
 Study level random effects
 Baseline hazard stratified by study
Model group definitions – Group 3 – Fixed effects and two study level random 
effects
Longitudinal sub-model
𝑌𝑘𝑖 = 𝛽10 + 𝛽11𝑡𝑖𝑚𝑒 + 𝛽12𝑡𝑟𝑒𝑎𝑡
+ 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒
+ 𝑏0𝑘
(3)
+ 𝑏1𝑘
(3)
𝑡𝑟𝑒𝑎𝑡 + 𝜀𝑘𝑖
Time-to-event sub-model
𝜆𝑘𝑖 𝑡 = 𝜆0 𝑡 exp 𝛽21𝑡𝑟𝑒𝑎𝑡 + 𝑊2
Association Structure
𝑊2 ∝ 𝑊1
𝑊2 = 𝛼
(2) 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒 + 𝛼(3) 𝑏0𝑘
(3)
+ 𝑏1𝑘
(3)
𝑡𝑟𝑒𝑎𝑡
Key – model components accounting for 
between study heterogeneity
 Longitudinal fixed effect coefficients
 Time-to-event fixed effect coefficients
 Study level random effects
 Baseline hazard stratified by study
Model group definitions – Group 4 – Fixed effects, stratified baseline hazard
Longitudinal sub-model
𝑌𝑘𝑖 = 𝛽10 + 𝛽11𝑡𝑖𝑚𝑒 + 𝛽12𝑡𝑟𝑒𝑎𝑡
+ 𝛽13𝑠𝑡𝑢𝑑𝑦 + 𝛽14𝑡𝑟𝑒𝑎𝑡 ∗ 𝑠𝑡𝑢𝑑𝑦
+ 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒
+ 𝜀𝑘𝑖
Time-to-event sub-model
𝜆𝑘𝑖 𝑡 = 𝜆0𝑘 𝑡 exp 𝛽21𝑡𝑟𝑒𝑎𝑡 + 𝑊2
Association Structure
𝑊2 ∝ 𝑊1
𝑊2 = 𝛼
(2) 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒
Key – model components accounting for 
between study heterogeneity
 Longitudinal fixed effect coefficients
 Time-to-event fixed effect coefficients
 Study level random effects
 Baseline hazard stratified by study
Model group definitions – Group 4 – Fixed effects, stratified baseline hazard
Longitudinal sub-model
𝑌𝑘𝑖 = 𝛽10 + 𝛽11𝑡𝑖𝑚𝑒 + 𝛽12𝑡𝑟𝑒𝑎𝑡
+ 𝛽13𝑠𝑡𝑢𝑑𝑦 + 𝛽14𝑡𝑟𝑒𝑎𝑡 ∗ 𝑠𝑡𝑢𝑑𝑦
+ 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒
+ 𝜀𝑘𝑖
Time-to-event sub-model
𝜆𝑘𝑖 𝑡 = 𝜆0𝑘 𝑡 exp 𝛽21𝑡𝑟𝑒𝑎𝑡 + 𝑊2
Association Structure
𝑊2 ∝ 𝑊1
𝑊2 = 𝛼
(2) 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒
Key – model components accounting for 
between study heterogeneity
 Longitudinal fixed effect coefficients
 Time-to-event fixed effect coefficients
 Study level random effects
 Baseline hazard stratified by study
Model group definitions – Group 5 – Fixed effects, stratified baseline hazard, 
one study level random effect
Longitudinal sub-model
𝑌𝑘𝑖 = 𝛽10 + 𝛽11𝑡𝑖𝑚𝑒 + 𝛽12𝑡𝑟𝑒𝑎𝑡
+ 𝛽13𝑠𝑡𝑢𝑑𝑦
+ 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒
+ 𝑏1𝑘
(3)
𝑡𝑟𝑒𝑎𝑡 + 𝜀𝑘𝑖
Time-to-event sub-model
𝜆𝑘𝑖 𝑡 = 𝜆0𝑘 𝑡 exp 𝛽21𝑡𝑟𝑒𝑎𝑡 + 𝑊2
Association Structure
𝑊2 ∝ 𝑊1
𝑊2 = 𝛼
(2) 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒 + 𝛼(3) 𝑏1𝑘
(3)
𝑡𝑟𝑒𝑎𝑡
Key – model components accounting for 
between study heterogeneity
 Longitudinal fixed effect coefficients
 Time-to-event fixed effect coefficients
 Study level random effects
 Baseline hazard stratified by study
Model group definitions – Group 5 – Fixed effects, stratified baseline hazard, 
one study level random effect
Longitudinal sub-model
𝑌𝑘𝑖 = 𝛽10 + 𝛽11𝑡𝑖𝑚𝑒 + 𝛽12𝑡𝑟𝑒𝑎𝑡
+ 𝛽13𝑠𝑡𝑢𝑑𝑦
+ 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒
+ 𝑏1𝑘
(3)
𝑡𝑟𝑒𝑎𝑡 + 𝜀𝑘𝑖
Time-to-event sub-model
𝜆𝑘𝑖 𝑡 = 𝜆0𝑘 𝑡 exp 𝛽21𝑡𝑟𝑒𝑎𝑡 + 𝑊2
Association Structure
𝑊2 ∝ 𝑊1
𝑊2 = 𝛼
(2) 𝑏0𝑘𝑖
(2)
+ 𝑏1𝑘𝑖
(2)
𝑡𝑖𝑚𝑒 + 𝛼(3) 𝑏1𝑘
(3)
𝑡𝑟𝑒𝑎𝑡
Key – model components accounting for 
between study heterogeneity
 Longitudinal fixed effect coefficients
 Time-to-event fixed effect coefficients
 Study level random effects
 Baseline hazard stratified by study
Results of one stage model fit – longitudinal treatment effect
Results of one stage model fit – longitudinal treatment effect
Results of one stage model fit – time-to-event treatment effect
Results of one stage model fit – association parameter(s)
Simulation work
• Range of simulations being conducted to asses a variety of scenarios (ongoing)
• Increasing number of studies
• Increasing number of longitudinal measurements
• Different levels of association at individual / study level
• Simulated data contains no changepoint
• Initial observations
• Issues with function with large datasets (due to sizes of some matrices used in survival sub-
model)
• One stage function appears to perform well for scenarios so far tested, but much more to be 
covered
Further work
• Continuation of simulation work
• Varying number of studies, size of data, level of association
• Model groups described here are being fitted to each scenario and examined to determine 
what model group preferable under a range of situations
• Expansion of joineRmeta package
• Additional sharing structures (current value, first derivative,…)
• Multiple longitudinal outcomes (e.g. modelling both systolic and diastolic blood pressure with 
time to death)
• Improvement of efficiency (faster running, solving of memory issues with large datasets)
Conclusions
• Range of methods available to model multi-study joint data.
• Methods available in R package, available on GitHub soon
• Methods currently restricted to single longitudinal outcome, one 
type of association structure…
• Further work needed to examine the association parameter 
estimation when changepoint included in the model.
• Choice of type of model to use (fixed interaction terms, study level 
random effects) should be made based on data structure (e.g. 
number of included studies) and investigation aims (e.g. is it 
important to have study specific estimates of treatment effect?)
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